Intellia Therapeutics Achieves Normal Human Alpha-1 Antitrypsin Protein Levels in Non-Human Primates Through Targeted Gene Insertion for the Treatment of AAT Deficiency
December 12, 2020 09:00 ET
|
Intellia Therapeutics, Inc.
Demonstrates modularity of Intellia’s in vivo liver insertion technology to durably restore protein, compared to traditional gene therapy Single-course administration of genome editing system...
Intellia Therapeutics Presents New Preclinical Data Supporting Its CRISPR/Cas9-Engineered TCR-T Cell Treatment for Acute Myeloid Leukemia at the 62nd ASH Annual Meeting
December 05, 2020 10:00 ET
|
Intellia Therapeutics, Inc.
Lead immuno-oncology development candidate NTLA-5001 shows high anti-tumor activity as promising cancer treatment in proof-of-concept mouse models of acute leukemiasProprietary process enhances tumor...
Yield10 Bioscience Researcher Dr. Meghna Malik to Present at the 4th CRISPR AgBio Congress 2020 Virtual Event
December 02, 2020 08:30 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced that Meghna Malik, Ph.D., Senior Director, will present...
HIV-Like Virus Eliminated from the Genomes of Primates; Excision BioTherapeutics Advancing the Innovation to Clinical Development
November 30, 2020 14:47 ET
|
Excision BioTherapeutics
San Francisco, CA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Taking a major step forward in HIV research, scientists at the Lewis Katz School of Medicine at Temple University have successfully edited SIV –...
Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations, H2 2020 Report
October 21, 2020 05:58 ET
|
Research and Markets
Dublin, Oct. 21, 2020 (GLOBE NEWSWIRE) -- The "Competitive Landscape Analysis of Recent Cell and Gene Therapy Innovations" report has been added to ResearchAndMarkets.com's offering. This...
Yield10 Bioscience Announces Completion of Harvesting for 2020 Field Test Program to Evaluate Novel Yield and Compositional Traits in Camelina and Canola
October 01, 2020 08:30 ET
|
Yield10 Bioscience, Inc.
WOBURN, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), an agricultural bioscience company, today announced it has completed the harvest for its 2020 Field Test...
Global Precision Medicine Market 2020-2030: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
September 30, 2020 03:04 ET
|
Research and Markets
Dublin, Sept. 30, 2020 (GLOBE NEWSWIRE) -- The "Global Precision Medicine Market: Focus on Ecosystem, Technology, Application, Country Data (21 Countries), and Competitive Landscape - Analysis and...
Global $4.88 Bn CRISPR & Cas Genes Market to 2027: Opportunities in the Expanding Gene & Cell Therapy Area & Government Fund In Genomic R&D
September 21, 2020 05:18 ET
|
Research and Markets
Dublin, Sept. 21, 2020 (GLOBE NEWSWIRE) -- The "Global CRISPR & Cas Genes Market Size, Share & Trends Analysis by Product & Service (Vector-based Cas, DNA-free Cas, Cell Line...
Excision BioTherapeutics Appoints Veteran Genome Editing Expert TJ Cradick, PhD as Chief Scientific Officer
August 04, 2020 12:00 ET
|
Excision BioTherapeutics
San Francisco, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Excision BioTherapeutics, a biotechnology company dedicated to curing viral infectious disease using CRISPR, today announced the appointment of TJ...
AAV Gene Therapy Pioneer Jude Samulski Develops Proprietary Regulated Gene Editing System
June 23, 2020 09:18 ET
|
Asklepios BioPharmaceutical, Inc.
RESEARCH TRIANGLE PARK, N.C. , June 23, 2020 (GLOBE NEWSWIRE) -- Asklepios BioPharmaceutical, Inc. (AskBio), a leading, clinical-stage adeno-associated virus (AAV) gene therapy company, today...